At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Mar 13, 2026 at 08:00 ET
Purple Biotech reported a significant net loss of $26.4 million for 2025, driven by a $20.5 million impairment charge related to the discontinuation of CM24 and NT219 programs. However, the company highlighted progress in its CAPTN-3 platform, including preclinical success and a $9.5 million cash position providing runway into 2027. Despite strong R&D advancements, the substantial loss and program discontinuations weigh on near-term fundamentals.
- Reported net loss of $26.4 million for 2025, up from $7.2 million in 2024, primarily due to a $20.5 million impairment charge on CM24 and NT219 programs
- Cash and cash equivalents totaled $9.5 million as of December 31, 2025, expected to fund operations into 2027
- Achieved key preclinical milestones for IM1240 and IM1305, including toxicology and manufacturing success, with data showing multi-arm anti-tumor activity
- R&D expenses decreased to $3.7 million in 2025 from $7.6 million in 2024 due to reduced clinical trial costs, despite increased CMC activities
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access